Abstract
Barrett’s oesophagus (BO) is the most important risk factor for oesophageal adenocarcinoma (OAC) and its incidence, as well as the cancer it precedes, is increasing. Evidence suggests that current methods of screening and surveillance are inadequate and therefore more clinically and cost effective techniques have been sought. With a better understanding of oesophageal adenocarcinoma and cancer in general, several genetic biomarkers have been identified which could be used to better diagnose and risk stratify patients. In this article we review current evidence for biomarkers in BO as well as identifying some of the problems yet to be overcome to allow their transition into clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
